+39 02 610346.1 - info@newron.com

Current partnerships

Current partnerships

To progress the development and maximise the potential value of its novel CNS compounds, Newron has entered into a number of strategic relationships with established pharmaceutical companies.

Current partners include:


In May 2012, Newron entered a strategic collaboration and licence agreement with Italian chemical and pharmaceutical company, Zambon, for Newron’s lead compound safinamide in all territories of the world with the exclusion of Japan and certain Asian territories. Since then, Newron has received significant success based regulatory milestone payments as well as customary royalty payments on future sales of safinamide in the licensed territories. Zambon has granted the commercialization rights to US WorldMeds for the U.S. US WorldMeds has then entered into a definitive agreement to sell Xadago, along with other CNS assets, to Supernus Pharmaceuticals. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel.

Meiji Seika Pharma Co., Ltd.

In February 2012 Newron signed a license agreement with Meiji Seika Pharma Co., Ltd., covering the research, development, manufacturing, and marketing of safinamide in Japan and key Asian territories. In April 2017, Meiji Seika and Eisai entered into a collaboration for the development and commercialisation of safinamide in Parkinson’s disease for Japan and Asia.